An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

Recruiting now · Phase 2

Conditions studied: Focal Onset Seizure, Primary Generalized Epilepsy

In brief

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures

Key facts

Study ID

NCT06908356

Run by

Praxis Precision Medicines

People needed

50

Starts

2025-01-10

Expected to finish

2025-07-01

Last updated by the study team

2025-04-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of focal onset seizures or idiopathic generalized tonic clonic seizures.
• Evidence by computed tomography (CT) or magnetic resonance imaging (MRI) in the past that has ruled out a progressive cause of epilepsy.
• Participant must have been receiving stable doses of allowable ASMs (a minimum of 1 and a maximum of 3 ASMs).
• Participant and/or caregiver (if applicable) self-reports at least 2 countable focal onset seizures per month for focal onset patients, or 1 countable generalized tonic-clonic seizure per month in the 3 months immediately prior to the Screening/Observation Period for PGTCS patients.

You may not qualify if…

• History of pseudo or psychogenic seizures, or cluster seizures only, within the 12-month period preceding study entry where the individual seizures cannot be counted, or an episode of convulsive status epilepticus requiring hospitalization and intubation in the 12 months prior to Screening.
• Planned epilepsy surgery during the course of the clinical trial.
• History of neurosurgery for seizures <1 year prior to enrollment, or radiosurgery <2 years prior to enrollment.
• Schizophrenia and obsessive-compulsive disorder, or other serious mental health disorders.
• Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt.
• Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.
• History of cardiac disease(s)/cardiac conduction disorders/or cardiac structural abnormality(ies).
• Is pregnant or breastfeeding at the time of Screening, or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.
• Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.
• Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.
• Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to Screening.

Where it is running

• Praxis Research Site — Phoenix, Arizona, United States (enrolling)
• Praxis Research Site — Miami Lakes, Florida, United States (enrolling)
• Praxis Research Site — Bethesda, Maryland, United States (enrolling)
• Praxis Research Site — Chesterfield, Missouri, United States (enrolling)
• Praxis Research Site — Hackensack, New Jersey, United States (enrolling)
• Praxis Research Site — Middletown, New York, United States (enrolling)
• Praxis Research Site — Round Rock, Texas, United States (enrolling)
• Praxis Research Site — Seabrook, Texas, United States (enrolling)
• Praxis Research Site — Heidelberg, Australia (enrolling)
• Praxis Research Site — Melbourne, Australia (enrolling)
• Praxis Research Site — Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.